

COMPANY PROFILE

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from Hemophilia, Primary Immunodeficiencies and other serious illnesses.

Kedrion puts people at its heart, placing a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.

Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand the patients' access to available treatments.

Headquartered in Italy, Kedrion Biopharma has a market presence in 100 countries. In the field of plasma derivatives, it is the world's 5th most important player and Italy's 1st. The company employs more than 2,500 people, over 1100 of whom are in Italy: over 37% of staff is under the age of 35 and women account for 50% of the workforce.

In Italy, Kedrion is a partner of the National Health System, which it concretely supports in the pursuit of self-sufficiency in the supply of plasma-derived products. At the same time, the company offers its expertise and its efforts to communities and health systems all over the world to achieve the same goal, in the attempt to help improve the quality of life of people with rare diseases.

The company manages the entire plasma transformation cycle (supply, production and distribution), on a vertical integration business model.

Our production plants are in Italy (Bolognana and Castelvechio Pascoli - which is nearing completion – near Lucca, and Sant'Antimo, near Naples), Hungary (in Gödöllő, near Budapest) and the United States (in Melville, New York).

Kedrion owns fully-operational plasma collection centers in the United States and Europe. In particular, a collection centre in Buffalo, State of New York, specializes in plasma with a high Anti-D antibody content, used to manufacture an Anti-D Immunoglobulin-based medicinal product for the prevention of Haemolytic Disease of the Fetus and the Newborn (HDFN).

kedrion.com